Efficient Transduction of Primary Vascular Cells by the Rare Adenovirus Serotype 49 Vector

Human Gene Therapy

Volumn 26, Issue 5, 2015, Pages 312-319

  Dakin, Rachel S ^a   Parker, Alan L ^a,b   Delles, Christian ^a   Nicklin, Stuart A ^a   Baker, Andrew H ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR;

ADENOVIRIDAE; ADENOVIRUS 49; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; ENDOTHELIUM CELL; EX VIVO STUDY; GENE TRANSFER; HUMAN; HUMAN CELL; SEROPREVALENCE; VASCULAR SMOOTH MUSCLE CELL; VIRAL GENE DELIVERY SYSTEM; CELL CULTURE; CELL LINE; CLASSIFICATION; CYTOLOGY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; IMMUNOLOGY; METABOLISM; SMOOTH MUSCLE CELL; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VIRAL TROPISM;

ADENOVIRIDAE;

ADENOVIRIDAE; CELL LINE; CELLS, CULTURED; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; TRANSDUCTION, GENETIC; VIRAL TROPISM;

EID: 84929713378     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2015.019     Document Type: Article

References (47)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart Disease and Stroke Statistics - 2012 Update: a report from the American Heart Association. Circulation 2012;125:e2-e220.
2. Pacak CA, Byrne BJ. AAV vectors for cardiac gene transfer: experimental tools and clinical opportunities. Mol Ther 2011;19:1582-1590.
3. 2+-ATPase in patients with advanced heart failure. Circulation 2011;124:304-313.
4. Wan S, George SJ, Berry C, et al. Vein graft failure: current clinical practice and potential for gene therapeutics. Gene Ther 2012;19:630-636.
5. Nicklin SA, Buening H, Dishart KL, et al. Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol Ther 2001;4:174-181.
6. White SJ, Nicklin SA, Büning H, et al. Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors. Circulation 2004;109:513-519.
7. George SJ, Wan S, Hu J, et al. Sustained reduction of vein graft neointima formation by ex vivo TIMP-3 gene therapy. Circulation 2011;124:S135-S142.
8. Akasaka Y, Ono I, Yamashita T, et al. Basic fibroblast growth factor promotes apoptosis and suppresses granulation tissue formation in acute incisional wounds. J Pathol 2004;203:710-720.
9. Varenne O, Pislaru S, Gillijns H, et al. Local adenovirus-mediated transfer of human endothelial nitric oxide synthase reduces luminal narrowing after coronary angioplasty in pigs. Circulation 1998;98:919-926.
10. Kibbe MR, Tzeng E, Gleixner SL, et al. Adenovirus-mediated gene transfer of human inducible nitric oxide synthase in porcine vein grafts inhibits intimal hyperplasia. J Vasc Surg 2001;34:156-165.
11. George SJ, Johnson JL, Angelini GD, et al. Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointimal formation in human saphenous vein. Hum Gene Ther 1998;9:867-877.
12. George SJ, Lloyd CT, Angelini GD, et al. Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3. Circulation 2000;101:296-304.
13. George SJ, Angelini GD, Capogrossi MC, et al. Wild-type p53 gene transfer inhibits neointima formation in human saphenous vein by modulation of smooth muscle cell migration and induction of apoptosis. Gene Ther 2001;8:668-676.
14. Kritz AB, Yu J, Wright PL, et al. In vivo modulation of Nogo-B attenuates neointima formation. Mol Ther 2008;16:1798-1804.
15. Lemarchand P, Jones M, Yamada I, et al. In vivo gene transfer and expression in normal uninjured blood vessels using replication-deficient recombinant adenovirus vectors. Circ Res 1993;72:1132-1138.
16. Rekhter MD, Simari RD, Work CW, et al. Gene transfer into normal and atherosclerotic human blood vessels. Circ Res 1998;82:1243-1252.
17. Parker A, White K, Lavery C, et al. Pseudotyping the adenovirus serotype 5 capsid with both the fibre and penton of serotype 35 enhances vascular smooth muscle cell transduction. Gene Ther 2013;20:1158-1164.
18. Vigl B, Zgraggen C, Rehman N, et al. Coxsackie- and adenovirus receptor (CAR) is expressed in lymphatic vessels in human skin and affects lymphatic endothelial cell function in vitro. Exp Cell Res 2009;315:336-347.
19. Sumida SM, Truitt DM, Lemckert AA, et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J Immunol 2005;174:7179-7185.
20. Bauer U, Flunker G, Bruss K, et al. Detection of antibodies against adenovirus protein IX, fiber, and hexon in human sera by immunoblot assay. J Clin Microbiol 2005;43:4426-4433.
21. Kuriyama S, Tominaga K, Kikukawa M, et al. Inhibitory effects of human sera on adenovirus-mediated gene transfer into rat liver. Anticancer Res 1998;18:2345-2351.
22. White KM, Alba R, Parker AL, et al. Assessment of a novel, capsid-modified adenovirus with an improved vascular gene transfer profile. J Cardiothoracic Surg 2013;8:183.
23. Gaggar A, Shayakhmetov DM, Lieber A. CD46 is a cellular receptor for group B adenoviruses. Nat Med 2003;9:1408-1412.
24. Abbink P, Lemckert AaC, Ewald BA, et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 2007;81:4654-4663.
25. Arnberg N, Kidd AH, Edlund K, et al. Initial interactions of subgenus D adenoviruses with A549 cellular receptors: sialic acid versus alpha(v) integrins. J Virol 2000;74:7691-7693.
26. Fallaux FJ, Bout A, Van Der Velde I, et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther 1998;9:1909-1917.
27. Southgate K, Newby AC. Serum-induced proliferation of rabbit aortic smooth muscle cells from the contractile state is inhibited by 8-Br-CAMP but not 8-Br-cGMP. Atherosclerosis 1990;82:113-123.
28. Lemckert AA, Grimbergen J, Smits S, et al. Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity. J Gen Virol 2006;87:2891-2899.
29. Vogels R, Zuijdgeest D, Van Rijnsoever R, et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 2003;77:8263-8271.
30. Alba R, Baker A, Nicklin S. Vector systems for prenatal gene therapy: principles of adenovirus design and production. In: Prenatal Gene Therapy. C Coutelle, SN Waddington, eds. (Humana Press, New York, NY). 2012; pp. 55-84.
31. Parker AL, Waddington SN, Buckley SMK, et al. Effect of neutralizing sera on factor X-mediated adenovirus serotype 5 gene transfer. J Virol 2009;83:479-483.
32. Thorner AR, Vogels R, Kaspers J, et al. Age dependence of adenovirus-specific neutralizing antibody titers in individuals from Sub-Saharan Africa. J Clin Microbiol 2006;44:3781-3783.
33. Jooss K, Chirmule N. Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy. Gene Ther 2003;10:955-963.
34. Sprangers MC, Lakhai W, Koudstaal W, et al. Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol 2003;41:5046-5052.
35. Wickham TJ, Mathias P, Cheresh DA, et al. Integrins ανβ3 and ανβ5 promote adenovirus internalization but not virus attachment. Cell 1993;73:309-319.
36. Roelvink PW, Mi Lee G, Einfeld DA, et al. Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. Science 1999;286:1568-1571.
37. Campbell JH, Kocher O, Skalli O, et al. Cytodifferentiation and expression of alpha-smooth muscle actin mRNA and protein during primary culture of aortic smooth muscle cells. Correlation with cell density and proliferative state. Arterioscler Thromb Vasc Biol 1989;9:633-643.
38. Verma S, Lovren F, Pan Y, et al. Pedicled no-touch saphenous vein graft harvest limits vascular smooth muscle cell activation: the PATENT saphenous vein graft study. Eur J Cardio Thorac Surg 2014;45:717-725.
39. Kipshidze N, Dangas G, Tsapenko M, et al. Role of the endothelium in modulating neointimal formation: vasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions. J Am Coll Cardiol 2004;44:733-739.
40. Schulick AH, Dong G, Newman KD, et al. Endothelium-specific in vivo gene transfer. Circ Res 1995;77:475-485.
41. Newman KD, Dunn PF, Owens JW, et al. Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia. J Clin Invest 1995;96:2955-2965.
42. Von Der Leyen HE, Gibbons GH, Morishita R, et al. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA 1995;92:1137-1141.
43. Rutanen J, Turunen AM, Teittinen M, et al. Gene transfer using the mature form of VEGF-D reduces neointimal thickening through nitric oxide-dependent mechanism. Gene Ther 2005;12:980-987.
44. Patel VI, Daniel S, Longo CR, et al. A20, a modulator of smooth muscle cell proliferation and apoptosis, prevents and induces regression of neointimal hyperplasia. FASEB J 2006;20:1418-1430.
45. Gupta R, Tongers J, Losordo DW. Human studies of angiogenic gene therapy. Circ Res 2009;105:724-736.
46. Jaski BE, Jessup ML, Mancini DM, et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail 2009;15:171-181.
47. Mast TC, Kierstead L, Gupta SB, et al. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 2010;28:950-957.